AstraZeneca
NEWS
China revenue in Q3 increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales.
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
Astra and its MedImmune division announced that two Phase III clinical trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.
Astra and Incyte are pushing forward on the development of immunotherapy combination treatments.
Astra signed a licensing deal with Mereo BioPharma to out license the oral inhibitor of neutrophil elastase to the smaller Mereo.
The former Biogen CEO is making waves at his new venture, Vir Biotechnology.
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
ADC Therapeutics announced it had raised $200M through an oversubscribed private placement.
JOBS
IN THE PRESS